HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...
HeartBeam BEAT recently secured FDA 510(k) clearance for its first-of-its-kind, cable-free synthesized 12-lead ECG technology, marking a major inflection point in the company’s mission to modernize ...
DiaCardia, a novel artificial intelligence model that can accurately identify individuals with prediabetes using either 12-lead or single-lead electrocardiogram (ECG) data, has been developed. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results